Drug Profile

Research programme: Graves' disease therapeutics - EpiVax

Alternative Names: Treg-BT - EpiVax; Tregitope-biotherapeutic - EpiVax

Latest Information Update: 28 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator EpiVax
Developer EpiVax; National Institute of Diabetes and Digestive and Kidney Diseases
Class Immunoglobulin fragments; Peptides
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jan 2022 No recent reports of development identified for preclinical development in Graves'-disease in USA (Parenteral)
19 Dec 2017 Preclinical trials in Graves' disease in USA (Parenteral)
19 Dec 2017 EpiVax plans a phase I trial for Graves' disease

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com